scholarly journals Vitamin D3 supplementation to improve fatigue in patients with advanced cancer.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 9097-9097
Author(s):  
Dragan Trivanovic ◽  
Stjepko Plestina ◽  
Renata Dobrilla-Dintinjana ◽  
Lorena Honovic ◽  
Lems Jerin ◽  
...  
Keyword(s):  
Vitamin D ◽  
Vitamin D3 ◽  
Serum Levels ◽  
Vitamin D Supplementation ◽  
Normal Serum ◽  
Fatigue Score ◽  
Increased Risk ◽  
Significant Difference ◽  
Vitamin D3 Supplementation ◽  
Cholecalciferol Supplementation

9097 Background: Fatigue is one of the most common symptoms of patients diagnosed with cancer. Vitamin D deficiency has been associated with an increased risk of mortality in oncology patients. We conducted a prospective vitamin D (cholecalciferol) supplementation study to analyse the response to oral D3 supplementation on fatigue in this population of chemo-naïve patients. Methods: Eligibility critera included life expectancy ≥ 6 months, ECOG PS 0-3, low serum 25-hydroxyvitamin D3 at the time of diagnosis (using cutoff value of 32 ng/mL), and normal serum calcium level. Cancer related fatigue was measured with the Functional Assessment of Cancer Therapy Fatigue module (FACT-F). Patients were randomized to receive oral supplementation with 2,000 IU of Vitamin D3 daily for 3 months with standard cancer treatment or to continue standard treatment without vit D3 supplementation. Primary endpoint was changes in the FACT-F scale. Secondary endpoints was improvement of vitamin D serum levels and safety. Results: 69 vit D deficient patients enrolled in the this study between November 2009 and November 2011 returned a baseline FACT-F. The mean serum 25(OH)D levels were 18.7 ng/ml (SD = 7.4) at baseline. Patients in experimental arm showed marked improvement from baseline in fatigue (p<0.05) and vitamin D serum levels after 3 months (p<0.001). There were significant difference in fatigue score in patients with experimental arm and control arm after 3 months of treatment (p< 0.001). Conclusions: Vitamin D supplementation resulted in a significant increase in Fatigue score and serum 25(OH)D levels in vitamin D deficient patients. Fatigue improve rapidly but remain worse in control arm. The safety profile of vitamin D in combination with chemotherapy or BSC was acceptable. [Table: see text]

scholarly journals Rapid and Effective Vitamin D Supplementation May Present Better Clinical Outcomes in COVID-19 (SARS-CoV-2) Patients by Altering Serum INOS1, IL1B, IFNg, Cathelicidin-LL37, and ICAM1

Nutrients ◽  
2021 ◽  
Vol 13 (11) ◽  
pp. 4047
Author(s):  
Mustafa Sait Gönen ◽  
Merve Alaylıoğlu ◽  
Emre Durcan ◽  
Yusuf Özdemir ◽  
Serdar Şahin ◽  
...  
Keyword(s):  
Vitamin D ◽  
Clinical Outcomes ◽  
Treatment Protocol ◽  
Serum Vitamin ◽  
Serum Levels ◽  
Vitamin D Supplementation ◽  
Vitamin D Metabolism ◽  
Serum Vitamin D ◽  
Increased Risk ◽  
Vitamin D3 Supplementation

Background: We aimed to establish an acute treatment protocol to increase serum vitamin D, evaluate the effectiveness of vitamin D3 supplementation, and reveal the potential mechanisms in COVID-19. Methods: We retrospectively analyzed the data of 867 COVID-19 cases. Then, a prospective study was conducted, including 23 healthy individuals and 210 cases. A total of 163 cases had vitamin D supplementation, and 95 were followed for 14 days. Clinical outcomes, routine blood biomarkers, serum levels of vitamin D metabolism, and action mechanism-related parameters were evaluated. Results: Our treatment protocol increased the serum 25OHD levels significantly to above 30 ng/mL within two weeks. COVID-19 cases (no comorbidities, no vitamin D treatment, 25OHD <30 ng/mL) had 1.9-fold increased risk of having hospitalization longer than 8 days compared with the cases with comorbidities and vitamin D treatment. Having vitamin D treatment decreased the mortality rate by 2.14 times. The correlation analysis of specific serum biomarkers with 25OHD indicated that the vitamin D action in COVID-19 might involve regulation of INOS1, IL1B, IFNg, cathelicidin-LL37, and ICAM1. Conclusions: Vitamin D treatment shortened hospital stay and decreased mortality in COVID-19 cases, even in the existence of comorbidities. Vitamin D supplementation is effective on various target parameters; therefore, it is essential for COVID-19 treatment.

scholarly journals Vitamin D and Serum Cytokines in a Randomized Clinical Trial

2010 ◽  
Vol 2010 ◽  
pp. 1-7 ◽  
Author(s):  
Eleanor Yusupov ◽  
Melissa Li-Ng ◽  
Simcha Pollack ◽  
James K. Yeh ◽  
Mageda Mikhail ◽  
...  
Keyword(s):  
Vitamin D ◽  
Placebo Group ◽  
Vitamin D3 ◽  
Intracellular Signaling ◽  
Final Visit ◽  
Active Vitamin ◽  
Gm Csf ◽  
Active Vitamin D ◽  
Significant Difference ◽  
Vitamin D3 Supplementation

Background. The role of vitamin D in the body's ability to fight influenza and URI's may be dependent on regulation of specific cytokines that participate in the host inflammatory response. The aim of this study was to test the hypothesis that vitamin D can influence intracellular signaling to regulate the production of cytokines.Subjects and Methods. This study was a 3-month prospective placebo-controlled trial of vitamin D3 supplementation in ambulatory adults [Li-Ng et al., 2009]. 162 volunteers were randomized to receive either 50 μg/d(2000 IU) of vitamin D3 or matching placebo. 25(OH)D and the levels of 10 different cytokines (IL-2, 4, 5, 6, 8, 10, 13, GM-CSF, IFN-γ, TNF-α) were measured in the serum of participants at baseline and the final visit. There were 6 drop-outs from the active vitamin D group and 8 from the placebo group.Results. In the active vitamin D group, we found a significant median percent decline in levels of GM-CSF (−62.9%,P<.0001), IFN-γ(−38.9%,P<.0001), IL-4 (−50.8%,P=.001), IL-8 (−48.4%,P<.0001), and IL-10 (−70.4%,P<.0001). In the placebo group, there were significant declines for GM-CSF (−53.2%,P=.0007) and IFN-γ(−34.4%,P=.0011). For each cytokine, there was no significant difference in the rate of decline between the two groups. 25(OH)D levels increased in the active vitamin D group from a mean of64.3±25.4 nmol/L to88.5±23.2 nmol/L.Conclusions. The present study did not show that vitamin D3 supplementation changed circulating cytokine levels among healthy adults.

scholarly journals Effects of Vitamin D3 Supplementation on Epigenetic Aging in Overweight and Obese African Americans With Suboptimal Vitamin D Status: A Randomized Clinical Trial

2018 ◽  
Vol 74 (1) ◽  
pp. 91-98 ◽  
Author(s):  
Li Chen ◽  
Yanbin Dong ◽  
Jigar Bhagatwala ◽  
Anas Raed ◽  
Ying Huang ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Dna Methylation ◽  
Vitamin D ◽  
African Americans ◽  
Randomized Clinical Trial ◽  
Vitamin D3 ◽  
Vitamin D Supplementation ◽  
P Value ◽  
Epigenetic Aging ◽  
Vitamin D3 Supplementation

Abstract Background We have previously shown that vitamin D supplementation increases telomerase activity, suggesting an anti-aging effect. In this study, we aim to test the hypothesis that vitamin D supplementation would slow down epigenetic aging, a new marker of biological aging. Methods A randomized clinical trial was previously conducted among 70 overweight/obese African Americans with serum 25-hydroxyvitamin D [25(OH)D] < 50 nmol/L, who were randomly assigned into four groups of 600 IU/d, 2,000 IU/d, 4,000 IU/d of vitamin D3 supplements or placebo followed by 16-week interventions. Whole genome-wide DNA methylation analysis was conducted in 51 participants. DNA methylation ages were calculated according to the Horvath and the Hannum methods. Methylation-based age acceleration index (∆Age) is defined as the difference between DNA methylation age and chronological age in years. Mixed-effects models were used to evaluate the treatment effects. Results Fifty-one participants (aged 26.1 ± 9.3 years, 16% are male) were included in the study. After the adjustment of multi-covariates, vitamin D3 supplementation of 4,000 IU/d was associated with 1.85 years decrease in Horvath epigenetic aging compared with placebo (p value = .046), and 2,000 IU/d was associated with 1.90 years decrease in Hannum epigenetic aging (p value = .044). Serum 25(OH)D concentrations were significantly associated with decreased Horvath ∆Age only (p values = .002), regardless of treatments. Conclusions Our results suggest that vitamin D supplementation may slow down Horvath epigenetic aging. But the effect on Hannum epigenetic aging is not conclusive. Large-scale and longer duration clinical trials are needed to replicate the findings.

Serum Vitamin D: Correlates of Baseline Concentration and Response to Supplementation in VITAL-DKD

2021 ◽  
Author(s):  
Cora M Best ◽  
Leila R Zelnick ◽  
Kenneth E Thummel ◽  
Simon Hsu ◽  
Christine Limonte ◽  
...  
Keyword(s):  
Vitamin D ◽  
Vitamin D3 ◽  
Parent Compound ◽  
Serum Vitamin ◽  
Vitamin D Supplementation ◽  
Total Serum ◽  
P Value ◽  
Hydroxyvitamin D ◽  
Serum Vitamin D ◽  
Vitamin D3 Supplementation

Abstract Context The effect of daily vitamin D supplementation on the serum concentration of vitamin D (the parent compound) may offer insight into vitamin D disposition. Objective To assess the total serum vitamin D response to vitamin D3 supplementation and whether it varies according to participant characteristics. To compare results with corresponding results for total serum 25-hydroxyvitamin D (25(OH)D), which is used clinically and measured in supplementation trials. Design Exploratory study within a randomized trial. Intervention 2,000 International Units of vitamin D3 per day (or matching placebo). Setting Community-based. Participants 161 adults (mean ± SD age 70 ± 6 years; 66% males) with type 2 diabetes. Main Outcome Measures Changes in total serum vitamin D and total serum 25(OH)D concentrations from baseline to year 2. Results At baseline, there was a positive, nonlinear relation between total serum vitamin D and total serum 25(OH)D concentrations. Adjusted effects of supplementation were a 29.2 (95% CI: 24.3, 34.1) nmol/L increase in serum vitamin D and a 33.4 (95% CI: 27.7, 39.2) nmol/L increase in serum 25(OH)D. Among those with baseline 25(OH)D &lt; 50 compared with ≥ 50 nmol/L, the serum vitamin D response to supplementation was attenuated (15.7 vs 31.2 nmol/L; interaction p-value = 0.02), whereas the serum 25(OH)D response was augmented (47.9 vs 30.7 nmol/L; interaction p-value = 0.05). Conclusions Vitamin D3 supplementation increases total serum vitamin D and 25(OH)D concentrations with variation according to baseline 25(OH)D, which suggests that 25-hydroxylation of vitamin D3 is more efficient when serum 25(OH)D concentration is low.

Prevalence of 25-hydroxyvitamin D deficiency in subgroups of elderly persons with anemia: association with anemia of inflammation

Blood ◽  
2011 ◽  
Vol 117 (10) ◽  
pp. 2800-2806 ◽  
Author(s):  
Todd S. Perlstein ◽  
Reena Pande ◽  
Nancy Berliner ◽  
Gary J. Vanasse
Keyword(s):  
Vitamin D ◽  
Vitamin D Deficiency ◽  
Serum Levels ◽  
The Elderly ◽  
Vitamin D Supplementation ◽  
World Health ◽  
Elderly Persons ◽  
Increased Risk ◽  
Health Organization ◽  
Anemia Of Inflammation

AbstractAnemia and vitamin D deficiency are conditions that both result in significant morbidity and increase with age. The potential relationship between them remains poorly understood, particularly in the elderly. We used the Third National Health and Nutrition Examination Survey to examine the association of vitamin D deficiency with anemia subtypes in persons aged ≥ 60 years. Vitamin D deficiency was defined as serum levels < 20 ng/mL, and anemia was defined according to World Health Organization criteria. Vitamin D deficiency was associated with anemia prevalence independent of age, sex, or race/ethnicity (odds ratio, 1.47; 95% confidence interval, 1.06-2.05; P = .02) and varied significantly by anemia subtype (P overall = .003). The prevalence of vitamin D deficiency was 33.3% in the nonanemic population, 56% in anemia of inflammation (AI; P = .008), and 33.0% in unexplained anemia (P = .55). Non-Hispanic blacks had a 7-fold increased risk of AI compared with whites, and this was partially attenuated after adjusting for vitamin D deficiency. These data show that vitamin D deficiency is associated with specific subtypes of anemia in the elderly, especially in those with AI. Vitamin D may suppress inflammatory pathways, and studies to determine whether vitamin D supplementation ameliorates AI are warranted.

Effect of Vitamin D Supplementation on Body Composition and Physical Fitness in Healthy Adults: A Double-Blind, Randomized Controlled Trial

2019 ◽  
Vol 75 (4) ◽  
pp. 231-237 ◽  
Author(s):  
Xiaomin Sun ◽  
Kumpei Tanisawa ◽  
Yuping Zhang ◽  
Tomoko Ito ◽  
Satomi Oshima ◽  
...  
Keyword(s):  
Vitamin D ◽  
Body Composition ◽  
Physical Fitness ◽  
Lean Body Mass ◽  
Body Mass ◽  
Vitamin D3 ◽  
Vitamin D Supplementation ◽  
Healthy Adults ◽  
Double Blind ◽  
Vitamin D3 Supplementation

Introduction: This study aimed to clarify whether 1 year of vitamin D3 supplementation has a direct effect on body composition and physical fitness in healthy adults. Methods: Ninety-five participants randomly received either 420 IU vitamin D3 per day (n = 48) or placebo (n = 47) in a double-blind manner for 1 year. Lean body mass and percentage body fat were determined. Physical fitness including hand grip strength, leg extension power and cardiorespiratory fitness (CRF) were assessed. Serum 25-hydroxyvitamin D (25[OH]D) and 1,25-dihydroxyvitamin D (1,25[OH]2D) concentrations were assessed using ELISA kits. Results: Serum 25(OH)D and (1,25[OH]2D) concentrations significantly increased by approximately 11.2 ± 9.2 ng/mL (pinteraction <0.001)and 7.0 ± 7.8 pg/mL (pinteraction <0.001) after 1 year of vitamin D3 supplementation respectively. Lean body mass significantly increased from 43.8 ± 9.6 to 44.3 ± 9.8 kg in vitamin D group, while no change was observed in placebo group (from 42.6 ± 8.9 to 42.4± 8.9 kg) after 1 year intervention. Furthermore, no treatment effects on other indicators of body composition and physical fitness were observed. Conclusions:One year of vitamin D supplementation effectively improves lean body mass, but not muscle strength and CRF in healthy adults.

scholarly journals Effect of Vitamin D Supplementation on Clinical and Radiographic Evaluation of Oral Rehabilitation with Osseointegrated Implants

2019 ◽  
Vol 21 (5) ◽  
pp. 518-522
Author(s):  
Adriano Piccolotto ◽  
Gisele Toyama ◽  
Mauro Busato ◽  
Adriane Yaeko Togashi
Keyword(s):  
Vitamin D ◽  
Serum Levels ◽  
Vitamin D Supplementation ◽  
Radiographic Evaluation ◽  
Oral Rehabilitation ◽  
Radiographic Findings ◽  
Vitamina D ◽  
Dental Implantation ◽  
Osseointegrated Implants ◽  
Significant Difference

Abstract   Vitamin D (VD) is important for the development and maintenance of bone tissue. This study used clinical and radiographic evaluations to analyze whether insufficient VD levels affect the periimplant health of patients with implant-supported prostheses. Data were collected for 33 patients with implant-supported prostheses: probing depth (PD); width of keratinized mucosa (wKM); bleeding index (mBI); periimplant plaque index (mPI); distance from implant to bone crest and VD level using chemiluminescence. After 1 year of implant-supported prosthesis installation, patients with levels under 30 ng/ml at baseline received 50000 IU of VD per week for 8 weeks (post treatment, PT), when clinical and radiographic evaluations were repeated for the control (n=19) and the VD (n=14) groups. Clinical and radiographic results were compared at baseline and at PT.  There were differences in PD (p=0.0247) and distance from implant to bone crest (p<0.0001), but there were not statistically different after supplementation.  wMK, mBI and mPI were not statistically different between groups.  VD levels were 24.95 ± 0.96 ng/mL in the VD group (42.42% of patients), whereas 57.57% of all participants had a mean VD value of 40.99 ± 1.23 ng/mL, a statistically significant difference (p = 0.0034). According to clinical and radiographic findings, VD serum levels do not seem to affect periimplant health. Keywords: Bone Density. Clinical Study. Dental Implantation.  ResumoA vitamina D (VD) é importante para o desenvolvimento e a manutenção do tecido ósseo. Este estudo clínico e radiográfico avaliou a reposição dos níveis de vitamina D na saúde periimplantar de pacientes com próteses implantossuportadas. Profundidade bolsa a sondagem (PS), largura da mucosa queratinizada (LMQ), sangramento a sondagem (mBI), presença de placa bacteriana (mPI), distância entre implante e cristas ósseas e dosagem de VD utilizando o teste de quimioluminescência, foram medidos em 33 pacientes. Pacientes com dosagens acima de 30 ng/ml foram classificados como suficientes de VD (grupo controle, n = 19). Pacientes com menos de 30ng/ml (grupo VD, n = 14) receberam, após 1 ano da instalação da prótese sobre implante, reposição de 50.000 UI por semana durante 8 semanas, quando os exames foram repetidos. Dados iniciais intragrupos, bem como dados iniciais e pós-tratamento (PT) intergrupos e intragrupos, foram comparados. Diferenças estatísticas foram encontradas em PS (p=0.0247) e distância entre crista óssea e implante (p<0.0001) entre os grupos, mas não após reposição. Não houve diferença em LMQ, mBI e mPI entre os grupos. O valor médio de VD do grupo VD foi 24,95±0.96 ng/ml para 42,42% dos pacientes, enquanto 57,57% da amostra apresentaram valor médio de 40,99±1.23 ng/ml, demonstrando diferença estatística (p=0.0034). A reposição de VD não parece influenciar os achados clínicos e radiográficos da saúde periimplantar. Palavras-chave: Densidade Óssea. Estudo Clínico. Implantação Dentária.

scholarly journals Potential Role of Vitamin D in the Elderly to Resist COVID-19 and to Slow Progression of Parkinson’s Disease

2020 ◽  
Vol 10 (5) ◽  
pp. 284 ◽  
Author(s):  
Casey A. Hribar ◽  
Peter H. Cobbold ◽  
Frank C. Church
Keyword(s):  
Older Adults ◽  
Parkinson’S Disease ◽  
Vitamin D ◽  
Parkinson's Disease ◽  
Vitamin D3 ◽  
The Elderly ◽  
Vitamin D Supplementation ◽  
Older Individuals ◽  
Related Quality ◽  
Cholecalciferol Supplementation

While we are still learning more about COVID-19, caused by the novel SARS-CoV-2 virus, finding alternative and already available methods to reduce the risk and severity of the disease is paramount. One such option is vitamin D, in the form of vitamin D3 (cholecalciferol) supplementation, due to its potential antiviral properties. It has become apparent that older individuals have a greater risk of developing severe COVID-19, and compared to younger adults, the elderly have lower levels of vitamin D due to a variety of biological and behavioral factors. Older adults are also more likely to be diagnosed with Parkinson’s disease (PD), with advanced age being the single greatest risk factor. In addition to its immune-system-modulating effects, it has been suggested that vitamin D supplementation plays a role in slowing PD progression and improving PD-related quality of life. We completed a review of the literature to determine the relationship between vitamin D, PD, and COVID-19. We concluded that the daily supplementation of 2000–5000 IU/day of vitamin D3 in older adults with PD has the potential to slow the progression of PD while also potentially offering additional protection against COVID-19.

The Effect of Vitamin D3 Supplementation on Serum BDNF, Dopamine, and Serotonin in Children with Attention-Deficit/Hyperactivity Disorder

2019 ◽  
Vol 18 (6) ◽  
pp. 496-501 ◽  
Author(s):  
Marzieh Seyedi ◽  
Fatemeh Gholami ◽  
Mahsa Samadi ◽  
Mahmoud Djalali ◽  
Mohammad Effatpanah ◽  
...  
Keyword(s):  
Vitamin D ◽  
Attention Deficit Hyperactivity Disorder ◽  
Vitamin D3 ◽  
Attention Deficit ◽  
Neurotrophic Factors ◽  
Serum Levels ◽  
Children With Adhd ◽  
Hyperactivity Disorder ◽  
Vitamin D3 Supplementation ◽  
Serum Bdnf

Background & Objective: Attention-Deficit/Hyperactivity Disorder (ADHD) is one of the most common psychiatric disorders in childhood. The exact etiology of this disease is unknown, but it is believed to be related to the disorder of catecholaminergic and serotonergic systems. Also, serum vitamin D levels in patients with ADHD is lower. Several studies have also shown the effect of vitamin D on the synthesis pathways of dopamine, serotonin, and a number of neurotrophic factors. Therefore, this study aimed to investigate the effect of vitamin D3 supplementation on serum levels of Brain-Derived Neurotrophic Factor (BDNF), dopamine, and serotonin in school-aged children with ADHD. Methods: Eighty-six children with ADHD were divided into two groups, based on randomized permuted blocks. Patients received 2000 IU vitamin D/day or a placebo for 12 weeks. Serum levels of BDNF, dopamine, serotonin, and 25-hydroxyvitamin D [25(OH)D] were measured at baseline and at the end of the study. Results: Serum levels of 25(OH)D and dopamine significantly increased in the vitamin D group, compared to the placebo group (p < 0.05). However, serum BDNF and serotonin levels did not change significantly. Conclusion: Vitamin D3 supplementation in children with ADHD can increase serum dopamine levels, but further studies are needed to determine the effects of vitamin D on neurotrophic factors and serotonin.

Sign in / Sign up

Export Citation Format

Share Document